FDA Approval Listing: Three Original PMAs In March
This article was originally published in The Gray Sheet
Executive Summary
FDA posted its official listing of March PMAs this week, including original PMA approvals for devices from Abbott Laboratories, Cochlear Ltd. and Roche Diagnostics. Also, average time-to-decision data for PMA supplements.
You may also be interested in...
Abbott Makes Good On IDev Buy With Supera Peripheral Stent Approval
Abbott announced PMA-approval of the Supera stent, which it gained in a $310 million acquisition of IDev Technologies last year. The approval gives Abbott a device specific for the superficial femoral artery, which the company says is one of the largest and fastest growing segments of the peripheral stent market.
New Product Briefs: Hearing Device; Volcano’s iFR Modality; St. Jude Pain Device
FDA approved Cochlear Ltd.’s Nucleus Hybrid L24 cochlear implant system, the first implantable device for adults with severe or profound sensorineural hearing loss. Volcano’s instant wave-Free Ratio (iFR) intravascular imaging modality is cleared based on ADVISE II results. More product news.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.